Ito Yasuhiro, Miyauchi Akira, Yamamoto Masashi, Kihara Minoru, Onoda Naoyoshi, Miya Akihiro
Department of Surgery, Kuma Hospital, Kobe, Japan.
Thyroid. 2025 Aug 11. doi: 10.1177/10507256251367242.
Thyroglobulin (Tg), stimulated or unstimulated by recombinant human thyrotropin (TSH), is a static marker of recurrent or persistent disease, and the Tg-doubling rate (Tg-DR) is a dynamic prognostic factor. This study evaluated the prognostic value of an unstimulated Tg (uTg) and Tg-DR papillary thyroid carcinoma (PTC). This retrospective study included 1818 Tg antibody (Tg-Ab)-negative patients who underwent curative intent total thyroidectomy for PTC without distant metastasis. The uTg was measured 1-3 months post-surgery under TSH suppression (<0.1 mIU/mL). We calculated the Tg-DR for patients, of whom postoperative Tg levels could be measured three or more times under TSH suppression. Eighty-eight (4.8%) and 32 (1.8%) patients had respective local and distant recurrences (median follow-up period, 7.2 years; 25th percentile 4.7 years, 75th percentile 9.8 years). Of 1818 patients, 131 had a uTg ≥3 ng/mL and were more likely to display local and distant recurrences in univariate and multivariable analyses ( < 0.001). We divided 1212 patients with no adjuvant radioactive iodine treatment, of whom uTg and Tg-DR data were available, into four categories A, uTg ≥3 ng/mL and Tg-DR ≥0.33/year; B, uTg <3 ng/mL and Tg-DR ≥0.33/year; C, uTg ≥3 ng/mL and Tg-DR <0.33/year; and D, uTg <3 ng/mL and Tg-DR <0.33/year. The lymph node recurrence-free survival rate was significantly worse from category A to D (A vs. B, < 0.001, hazard ratio or HR [CI]: 5.083 [1.994-12.955]; B vs. C, = 0.001, HR [CI]: 2.654 [1.462-4.824]; C vs. D, < 0.001, HR [CI]: 27.420 [15.100-4.980]). The distant recurrence-free survival rate (DR-FS) of category B did not differ from that of category C ( = 0.419), but DR-FS of category D was better ( < 0.001) than those of B and C, and that of category A tended to be worse ( = 0.087) compared with those of B and C. Patients in category A, categories B and C, and category D could thus be classified as high-risk, intermediate-risk, and low-risk for distant recurrence, respectively. This study demonstrates the prognostic value of postoperative uTg and Tg-DR in Tg-Ab-negative patients with PTC under TSH suppression after total thyroidectomy. Prospective studies are needed to confirm these findings.
在重组人促甲状腺激素(TSH)刺激或未刺激的情况下,甲状腺球蛋白(Tg)是复发或持续性疾病的静态标志物,而Tg倍增率(Tg-DR)是一个动态预后因素。本研究评估了未刺激的Tg(uTg)和Tg-DR在甲状腺乳头状癌(PTC)中的预后价值。这项回顾性研究纳入了1818例Tg抗体(Tg-Ab)阴性且因PTC接受了根治性全甲状腺切除术且无远处转移的患者。术后1至3个月,在TSH抑制状态下(<0.1 mIU/mL)测量uTg。我们计算了术后在TSH抑制状态下可测量三次或更多次Tg水平的患者的Tg-DR。88例(4.8%)和32例(1.8%)患者分别出现局部和远处复发(中位随访期7.2年;第25百分位数4.7年,第75百分位数9.8年)。在1818例患者中,131例uTg≥3 ng/mL,在单因素和多因素分析中更有可能出现局部和远处复发(<0.001)。我们将1212例未接受辅助放射性碘治疗且有uTg和Tg-DR数据的患者分为四类:A类,uTg≥3 ng/mL且Tg-DR≥0.33/年;B类,uTg<3 ng/mL且Tg-DR≥0.33/年;C类,uTg≥3 ng/mL且Tg-DR<0.33/年;D类,uTg<3 ng/mL且Tg-DR<0.33/年。从A类到D类,无淋巴结复发生存率显著变差(A类与B类比较,<0.001,风险比或HR[CI]:5.083[1.994 - 12.955];B类与C类比较,=0.001,HR[CI]:2.654[1.462 - 4.824];C类与D类比较,<0.001,HR[CI]:27.420[15.100 - 4.980])。B类的无远处复发生存率(DR-FS)与C类无差异(=0.419),但D类的DR-FS优于B类和C类(<0.001),A类的DR-FS与B类和C类相比倾向于更差(=0.087)。因此,A类、B类和C类以及D类患者可分别归类为远处复发的高风险、中风险和低风险患者。本研究证明了术后uTg和Tg-DR在全甲状腺切除术后TSH抑制状态下Tg-Ab阴性PTC患者中的预后价值。需要前瞻性研究来证实这些发现。